These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 8806289)

  • 1. Randomised controlled trial of conservation therapy for breast cancer: 6-year analysis of the Scottish trial. Scottish Cancer Trials Breast Group.
    Forrest AP; Stewart HJ; Everington D; Prescott RJ; McArdle CS; Harnett AN; Smith DC; George WD
    Lancet; 1996 Sep; 348(9029):708-13. PubMed ID: 8806289
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Postoperative radiotherapy in women with early operable breast cancer (Scottish Breast Conservation Trial): 30-year update of a randomised, controlled, phase 3 trial.
    Williams LJ; Kunkler IH; Taylor KJ; Dunlop J; Piper T; Caldwell J; Jack W; Loane JF; Elder K; Bartlett JMS; Dixon JM; Cameron DA
    Lancet Oncol; 2024 Sep; 25(9):1213-1221. PubMed ID: 39127062
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Possibility of conservative local treatment after combined chemotherapy and preoperative irradiation for locally advanced noninflammatory breast cancer.
    Touboul E; Buffat L; Lefranc JP; Blondon J; Deniaud E; Mammar H; Laugier A; Schlienger M
    Int J Radiat Oncol Biol Phys; 1996 Mar; 34(5):1019-28. PubMed ID: 8600084
    [TBL] [Abstract][Full Text] [Related]  

  • 4. No breast cancer subgroup can be spared postoperative radiotherapy after breast-conserving surgery. Fifteen-year results from the Swedish Breast Cancer Group randomised trial, SweBCG 91 RT.
    Killander F; Karlsson P; Anderson H; Mattsson J; Holmberg E; Lundstedt D; Holmberg L; Malmström P
    Eur J Cancer; 2016 Nov; 67():57-65. PubMed ID: 27614164
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial.
    Overgaard M; Hansen PS; Overgaard J; Rose C; Andersson M; Bach F; Kjaer M; Gadeberg CC; Mouridsen HT; Jensen MB; Zedeler K
    N Engl J Med; 1997 Oct; 337(14):949-55. PubMed ID: 9395428
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 21-Gene Recurrence Score and Locoregional Recurrence in Node-Positive/ER-Positive Breast Cancer Treated With Chemo-Endocrine Therapy.
    Mamounas EP; Liu Q; Paik S; Baehner FL; Tang G; Jeong JH; Kim SR; Butler SM; Jamshidian F; Cherbavaz DB; Sing AP; Shak S; Julian TB; Lembersky BC; Wickerham DL; Costantino JP; Wolmark N
    J Natl Cancer Inst; 2017 Jan; 109(4):. PubMed ID: 28122895
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of c-erbB(2) and estrogen receptor status on survival of women with primary breast cancer treated with adjuvant cyclophosphamide/methotrexate/fluorouracil.
    Miles DW; Harris WH; Gillett CE; Smith P; Barnes DM
    Int J Cancer; 1999 Aug; 84(4):354-9. PubMed ID: 10404085
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant ovarian ablation versus CMF chemotherapy in premenopausal women with pathological stage II breast carcinoma: the Scottish trial. Scottish Cancer Trials Breast Group and ICRF Breast Unit, Guy's Hospital, London.
    Lancet; 1993 May; 341(8856):1293-8. PubMed ID: 8098446
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen receptor-negative tumors: eight-year results from National Surgical Adjuvant Breast and Bowel Project (NSABP) B-13 and first report of findings from NSABP B-19 comparing methotrexate and fluorouracil with conventional cyclophosphamide, methotrexate, and fluorouracil.
    Fisher B; Dignam J; Mamounas EP; Costantino JP; Wickerham DL; Redmond C; Wolmark N; Dimitrov NV; Bowman DM; Glass AG; Atkins JN; Abramson N; Sutherland CM; Aron BS; Margolese RG
    J Clin Oncol; 1996 Jul; 14(7):1982-92. PubMed ID: 8683228
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thirty-year follow-up of chemo/hormonal therapy in node-positive breast cancer.
    Gordon NH; Silverman P; Lasheen W; Meinert J; Siminoff LA
    Breast Cancer Res Treat; 2007 May; 102(3):301-12. PubMed ID: 17033926
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemotherapy versus observation in high-risk node-negative breast cancer patients.
    Mansour EG; Eudey L; Tormey DC; Shatila AH; Osborne CK; Gilchrist KW; Cooper MR; Falkson G
    J Natl Cancer Inst Monogr; 1992; (11):97-104. PubMed ID: 1627437
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomised trial of high-dose chemotherapy and haemopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvement.
    Rodenhuis S; Richel DJ; van der Wall E; Schornagel JH; Baars JW; Koning CC; Peterse JL; Borger JH; Nooijen WJ; Bakx R; Dalesio O; Rutgers E
    Lancet; 1998 Aug; 352(9127):515-21. PubMed ID: 9716055
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant CMFP versus CMFP plus tamoxifen versus observation alone in postmenopausal, node-positive breast cancer patients: three-year results of an Eastern Cooperative Oncology Group study.
    Taylor SG; Kalish LA; Olson JE; Cummings F; Bennett JM; Falkson G; Tormey DC; Carbone PP
    J Clin Oncol; 1985 Feb; 3(2):144-54. PubMed ID: 3881561
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials.
    Haviland JS; Owen JR; Dewar JA; Agrawal RK; Barrett J; Barrett-Lee PJ; Dobbs HJ; Hopwood P; Lawton PA; Magee BJ; Mills J; Simmons S; Sydenham MA; Venables K; Bliss JM; Yarnold JR;
    Lancet Oncol; 2013 Oct; 14(11):1086-1094. PubMed ID: 24055415
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined chemotherapy and radiotherapy for patients with breast cancer and extensive nodal involvement.
    Ung O; Langlands AO; Barraclough B; Boyages J
    J Clin Oncol; 1995 Feb; 13(2):435-43. PubMed ID: 7844606
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomised trial of chemo-endocrine therapy, endocrine therapy, and mastectomy alone in postmenopausal patients with operable breast cancer and axillary node metastasis.
    Ludwig Breast Cancer Study Group
    Lancet; 1984 Jun; 1(8389):1256-60. PubMed ID: 6144974
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
    Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
    BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term results of combined-modality therapy for locally advanced breast cancer with ipsilateral supraclavicular metastases: The University of Texas M.D. Anderson Cancer Center experience.
    Brito RA; Valero V; Buzdar AU; Booser DJ; Ames F; Strom E; Ross M; Theriault RL; Frye D; Kau SW; Asmar L; McNeese M; Singletary SE; Hortobagyi GN
    J Clin Oncol; 2001 Feb; 19(3):628-33. PubMed ID: 11157012
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvant treatment for early breast cancer: the Ludwig breast cancer studies.
    Goldhirsch A; Gelber R
    NCI Monogr; 1986; (1):55-70. PubMed ID: 3774016
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.
    Lancet; 1998 Sep; 352(9132):930-42. PubMed ID: 9752815
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.